BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer

Tatsuya Morikawa, Ryo Inada, Takeshi Nagasaka, Yoshiko Mori, Hiroyuki Kishimoto, Takashi Kawai, Yuzo Umeda, Hideyuki Mishima, Ajay Goel, Toshiyoshi Fujiwara

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


In stage IV colorectal cancer (CRC), initial resection of the primary tumor is considered to be an important strategy for improving disease outcome. However, there is no consensus on the timing as to when the surgical intervention of the primary tumor should occur. The present study hypothesizes that genetic profiles in CRC may indicate the appropriate treatment strategies for patients with stage IV CRC, and a cohort of 113 patients with stage IV CRC resected primary lesions at various periods were analyzed for the presence of mutations in the KRAS, exon 2, and BRAF genes, exon 15, and for the microsatellite instability status of the tumor. These data were additionally correlated with various clinicopathological features. Although BRAF-mutant was revealed to be an independent negative prognostic factor in stage IV CRC (HR, 8.42; 95% confidence interval, 2.72-26.02), BRAF-mutant samples exhibited better prognoses if they were treated with chemotherapy prior to tumor resection. Thus, the presence of BRAF mutations provides a compelling rationale for the establishment of intensive upfront chemotherapy to improve survival in stage IV CRC.

Original languageEnglish
Pages (from-to)2195-2201
Number of pages7
JournalOncology Letters
Issue number2
Publication statusPublished - Feb 2018


  • BRAF mutation
  • Colorectal cancer
  • KRAS mutation
  • Microsatellite instability
  • Stage IV
  • Upfront chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer'. Together they form a unique fingerprint.

Cite this